Quality by Design: Adding Another Dimension to Outsourcing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality by Design: Adding Another Dimension to Outsourcing
FDA's quality-by-design initiative is gradually reshaping the paradigm for pharmaceutical manufacturing and the opportunities and challenges in outsourcing.


Pharmaceutical Technology
Volume 34, Issue 1, pp. 40-44


PHOTO: PASIEKA/SPS, GETTY IMAGES
The US Food and Drug Administration's quality-by-design (QbD) initiative, a science- and risk-based approach to manufacturing, adds another layer to the relationship between sponsor companies and contract manufacturers. Enhanced process understanding is at the core of QbD, which is deepening the nature of outsourcing.

A regulatory framework

At one level, QbD simply extends the collaborative nature inherent in an outsourced relationship. "Contract manufacturers can apply the same mindset to process development and manufacturing as the sponsoring company. We encourage the use of quality risk management for both design of the process-control strategy as well as for life-cycle management," says Christine M.V. Moore, acting deputy office director of the Office of New Drug Quality Assessment in the Center for Drug Evaluation and Research at the US Food and Drug Administration. "A large part of a QbD approach is enhanced understanding of the product and process. This understanding should be openly communicated between the contract manufacturing organization and the sponsor such that good science and risk-based decisions can be made."

A sponsor-company perspective


ICH Q10 Pharmaceutical Quality System and outsourcing
As drug companies adopt QbD in their own development and manufacturing, their expectations of contract-service providers are changing. "There are several possible scenarios in which a QbD approach to development can impact the relationship between a sponsor and a contractor," says Mary Oates, vice-president of global quality operations at Pfizer Global Manufacturing (New York). The first scenario is when the sponsor is fully responsible for development and transfers the final process to the vendor. A second scenario would be when the sponsor and firm collaborate on the development effort.

Under the first case, sponsors historically have interacted with contract-service providers to address quality, supply, and technical needs and may also engage in continuous improvement activities. "These items will continue to be important, but QbD will require far greater collaboration, beginning with the technical transfer and continuing as long as the contract-service providers manufacture for the sponsor," says Oates.


On the horizon...
She offers an example of that greater collaboration and the continual need to garner process understanding under QbD. "For example, the contract-service providers must have full access to development data in order to understand the allowable design space, and if and when changes can be made within this design space, to ensure the product remains consistent," she says. "Once routine manufacturing begins, every lot that is manufactured becomes part of the overall body of knowledge, and the data collected must be assessed to verify that the product and process are performing as expected. This involves much more analysis than simply comparing results to a list of specifications. The contract-service providers must be capable of performing and interpreting this analysis in a routine manufacturing environment, alerting the sponsor to any changes observed and ensuring that required adjustments to the product or the process are implemented."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here